{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T04:57:19Z","timestamp":1793422639250,"version":"4.5.0"},"reference-count":25,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"<jats:sec id=\"ab-zoi221310-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Treatment with immune checkpoint inhibitors (ICIs) has increased survival in patients with advanced malignant melanoma but can be associated with a wide range of immune-related adverse events (irAEs). The role of human leukocyte antigen (HLA)\u2013DR alleles in conferring irAE risk has not been well studied.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-zoi221310-5\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the association between irAEs and treatment response, survival, and the presence of HLA-DR alleles after ICI therapy in advanced melanoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-zoi221310-6\">\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>This case-control study used the patient registry and biobanked samples from the tertiary referral University of Colorado Cancer Center. Specimens and clinical data were collected between January 1, 2010, and December 31, 2021. Patients with advanced (stage III unresectable and stage IV) melanoma who received ICI therapy (n\u2009=\u2009132) were included in the analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-zoi221310-7\">\n                    <jats:title>Exposures<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors (anti\u2013cytotoxic T-lymphocyte antigen 4, anti\u2013programmed cell death protein 1 or its ligand, or the combination) for the treatment of advanced melanoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-zoi221310-8\">\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>The association between irAEs and response to therapy, survival, and HLA-DR alleles.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-zoi221310-9\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among the cohort of 132 patients with advanced melanoma (mean [SD] age, 63.4\u2009[7.2] years; 85 men [64%] and 47 women [36%]) treated with ICIs, 73 patients had at least 1 irAE and 59 did not have an irAE. Compared with patients without an irAE, patients with an irAE had higher treatment response rates (50 of 72 [69%] vs 28 of 57 [49%];\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.02) and increased survival (median, 4.8 [IQR, 0.2-9.6] vs 3.2 [IQR, 0.1-9.2] years;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.02). Specific HLA-DR alleles were associated with the type of irAE that developed: 7 of 10 patients (70%) who developed type 1 diabetes had DR4; 6 of 12 (50%) who developed hypothyroidism had DR8; 5 of 8 (63%) who developed hypophysitis had DR15; 3 of 5 (60%) who developed pneumonitis had DR1; and 8 of 15 (53%) who developed hepatitis had DR4.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-zoi221310-10\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>These findings suggest that IrAEs are associated with treatment response rates and increased survival after ICI therapy for advanced melanoma. Because distinct HLA-DR alleles are associated with given adverse events, HLA genotyping before ICI therapy may aid in identifying risk for specific irAEs that could develop with such treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2022.46400","type":"journal-article","created":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T11:03:21Z","timestamp":1670929401000},"page":"e2246400","source":"Crossref","is-referenced-by-count":39,"title":["Analysis of Human Leukocyte Antigen DR Alleles, Immune-Related Adverse Events, and Survival Associated With Immune Checkpoint Inhibitor Use Among Patients With Advanced Malignant Melanoma"],"prefix":"10.1001","volume":"5","author":[{"given":"Halis Kaan","family":"Akturk","sequence":"first","affiliation":[{"name":"Barbara Davis Center for Diabetes, University of Colorado School of Medicine, Aurora"},{"name":"Department of Pediatrics, University of Colorado School of Medicine, Aurora"},{"name":"Department of Medicine, University of Colorado School of Medicine, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasey L.","family":"Couts","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Colorado School of Medicine, Aurora"},{"name":"University of Colorado Cancer Center, University of Colorado School of Medicine, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin E.","family":"Baschal","sequence":"additional","affiliation":[{"name":"Barbara Davis Center for Diabetes, University of Colorado School of Medicine, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kagan E.","family":"Karakus","sequence":"additional","affiliation":[{"name":"Barbara Davis Center for Diabetes, University of Colorado School of Medicine, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Van Gulick","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Colorado School of Medicine, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline A.","family":"Turner","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Colorado School of Medicine, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Pyle","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Colorado School of Medicine, Aurora"},{"name":"Department of Biostatistics and Informatics, Colorado School of Public Health, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William A.","family":"Robinson","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Colorado School of Medicine, Aurora"},{"name":"University of Colorado Cancer Center, University of Colorado School of Medicine, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron W.","family":"Michels","sequence":"additional","affiliation":[{"name":"Barbara Davis Center for Diabetes, University of Colorado School of Medicine, Aurora"},{"name":"Department of Pediatrics, University of Colorado School of Medicine, Aurora"},{"name":"Department of Medicine, University of Colorado School of Medicine, Aurora"},{"name":"Department of Immunology, University of Colorado School of Medicine, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2022,12,13]]},"reference":[{"issue":"12","key":"zoi221310r1","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1001\/jama.2018.22119","article-title":"Adverse events associated with immune checkpoint inhibitors.","volume":"321","author":"Akturk","year":"2019","journal-title":"JAMA"},{"issue":"7","key":"zoi221310r2","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1001\/jamaoncol.2019.0413","article-title":"PD-1 immune checkpoint inhibitors and immune-related adverse events: understanding the upside of the downside of checkpoint blockade.","volume":"5","author":"Davar","year":"2019","journal-title":"JAMA Oncol"},{"issue":"3","key":"zoi221310r3","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.3461","article-title":"Immune-related adverse events after immune checkpoint inhibitors for melanoma among older adults.","volume":"5","author":"Schonfeld","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"2","key":"zoi221310r4","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis.","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol"},{"issue":"3","key":"zoi221310r5","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.1611","article-title":"Immune checkpoint inhibitors and immune-related adverse events in patients with advanced melanoma: a systematic review and network meta-analysis.","volume":"3","author":"Chang","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"12","key":"zoi221310r6","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1056\/NEJMc1801663","article-title":"Adverse events associated with immune checkpoint blockade.","volume":"378","author":"Akturk","year":"2018","journal-title":"N Engl J Med"},{"issue":"10","key":"zoi221310r7","doi-asserted-by":"publisher","first-page":"3589","DOI":"10.1210\/jc.2018-01430","article-title":"PD-1 inhibitor immune-related adverse events in patients with preexisting endocrine autoimmunity.","volume":"103","author":"Akturk","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"zoi221310r8","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nri.2017.143","article-title":"HLA variation and disease.","volume":"18","author":"Dendrou","year":"2018","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"zoi221310r9","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics.","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"key":"zoi221310r10","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1196\/annals.1288.047","article-title":"Ethnic differences in the associations between the HLA-DRB1*04 subtypes and type 1 diabetes.","volume":"1005","author":"Rewers","year":"2003","journal-title":"Ann N Y Acad Sci"},{"issue":"4","key":"zoi221310r11","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.2337\/db07-1331","article-title":"HLA DR-DQ haplotypes and genotypes and type 1 diabetes risk: analysis of the Type 1 Diabetes Genetics Consortium families.","volume":"57","author":"Erlich","year":"2008","journal-title":"Diabetes"},{"issue":"3","key":"zoi221310r12","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1056\/NEJM197807202990306","article-title":"Hashimoto\u2019s thyroiditis is associated with HLA-DRw3.","volume":"299","author":"Moens","year":"1978","journal-title":"N Engl J Med"},{"issue":"4","key":"zoi221310r13","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1046\/j.1365-2265.2001.01356.x","article-title":"Histocompatibility leucocyte antigens and closely linked immunomodulatory genes in autoimmune thyroid disease.","volume":"55","author":"Hunt","year":"2001","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"zoi221310r14","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1002\/(ISSN)1527-3350","article-title":"Susceptibility to autoimmune chronic active hepatitis: human leukocyte antigens DR4 and A1-B8-DR3 are independent risk factors.","volume":"13","author":"Donaldson","year":"1991","journal-title":"Hepatology"},{"issue":"18","key":"zoi221310r15","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1056\/NEJMoa0908547","article-title":"Variant of TYR and autoimmunity susceptibility loci in generalized vitiligo.","volume":"362","author":"Jin","year":"2010","journal-title":"N Engl J Med"},{"issue":"4","key":"zoi221310r16","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1001\/jamaoncol.2019.5570","article-title":"Association between immune-related adverse events and recurrence-free survival among patients with stage III melanoma randomized to receive pembrolizumab or placebo: a secondary analysis of a randomized clinical trial.","volume":"6","author":"Eggermont","year":"2020","journal-title":"JAMA Oncol"},{"issue":"3","key":"zoi221310r17","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","article-title":"Association of immune-related adverse events with nivolumab efficacy in non\u2013small-cell lung cancer.","volume":"4","author":"Haratani","year":"2018","journal-title":"JAMA Oncol"},{"issue":"12","key":"zoi221310r18","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1001\/jamaoncol.2020.5012","article-title":"Multisystem immune-related adverse events associated with immune checkpoint inhibitors for treatment of non\u2013small cell lung cancer.","volume":"6","author":"Shankar","year":"2020","journal-title":"JAMA Oncol"},{"issue":"9","key":"zoi221310r19","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1111\/dme.v36.9","article-title":"Immune checkpoint inhibitor-induced type 1 diabetes: a systematic review and meta-analysis.","volume":"36","author":"Akturk","year":"2019","journal-title":"Diabet Med"},{"issue":"8","key":"zoi221310r20","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.2337\/dbi18-0002","article-title":"Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors.","volume":"67","author":"Stamatouli","year":"2018","journal-title":"Diabetes"},{"issue":"3","key":"zoi221310r21","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.mayocp.2019.12.009","article-title":"Immune checkpoint inhibitor-induced type 1 diabetes: an underestimated risk.","volume":"95","author":"Akturk","year":"2020","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"zoi221310r22","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002493","article-title":"Anti-pituitary antibodies and susceptible human leukocyte antigen alleles as predictive biomarkers for pituitary dysfunction induced by immune checkpoint inhibitors.","volume":"9","author":"Kobayashi","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"9","key":"zoi221310r23","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.3390\/cells9091964","article-title":"HLA expression correlates to the risk of immune checkpoint inhibitor-induced pneumonitis.","volume":"9","author":"Correale","year":"2020","journal-title":"Cells"},{"issue":"6375","key":"zoi221310r24","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1126\/science.aao4572","article-title":"Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy.","volume":"359","author":"Chowell","year":"2018","journal-title":"Science"},{"issue":"1","key":"zoi221310r25","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/S1470-2045(21)00582-9","article-title":"HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study.","volume":"23","author":"Naranbhai","year":"2022","journal-title":"Lancet Oncol"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2799441\/akturk_2022_oi_221310_1670339201.56871.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T11:03:23Z","timestamp":1670929403000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2799441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,13]]},"references-count":25,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.46400","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,13]]}}}